PMCB
PHARMACYTE BIOT (PMCB)
NASDAQ
$0.73-$0.02 (-2.82%)
Price as of Jun 03, 2026 5:04 PM EDT
  • $9.0M
    Market Cap
  • -31.71%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
04/30/2025
04/30/2024
04/30/2023
04/30/2022
Income Statement
Total Operating Revenue
0
N/A
0
N/A
0
N/A
0
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
0
N/A
0
N/A
0
N/A
0
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
-438,416
+7.60%
-407,431
-13.04%
-468,536
-32.19%
-690,937
-24.59%
Depreciation and Amortization Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Operating Expenses
4.4M
-48.62%
8.5M
+31.98%
6.5M
+46.98%
4.4M
+21.23%
Operating Profit
-4.4M
-48.62%
-8.5M
+31.98%
-6.5M
+46.98%
-4.4M
+21.23%
Interest Income
1.4M
-58.35%
3.4M
+75.42%
1.9M
+1,129.03%
157,645
N/A
Interest Expense
N/A
N/A
N/A
N/A
0
+100.00%
-509
-83.29%
Interest Income and Expense and Net
1.4M
-58.35%
3.4M
+75.42%
1.9M
+1,133.01%
157,136
+5,258.77%
Total Nonoperating Income and Expense
35.0M
+295.69%
8.9M
+313.82%
2.1M
+1,299.71%
152,853
+113.05%
Income before Taxes
23.4M
+235.53%
-17.2M
+167.02%
-6.5M
+46.98%
-4.4M
+21.23%
Income Taxes
0
N/A
0
N/A
0
N/A
0
N/A
Extraordinary Items
1.6M
0.00%
1.6M
N/A
N/A
N/A
N/A
N/A
Net Income
23.4M
+6,899.61%
333,763
+107.73%
-4.3M
+1.81%
-4.2M
+19.37%
Net Income from Continuing Operations Applicable to Common
23.4M
+235.53%
-17.2M
+299.38%
-4.3M
+1.81%
-4.2M
+19.37%
Basic EPS and Net Income
3.19
+277.22%
-1.80
+718.18%
-0.22
-18.52%
-0.27
-88.98%
Diluted EPS and Net Income
3.19
+277.22%
-1.80
+718.18%
-0.22
-18.52%
-0.27
-88.98%
Basic Weighted Average Shares
7.3M
-23.50%
9.6M
-50.84%
19.5M
+25.56%
15.5M
+971.73%
Diluted Weighted Average Shares
7.3M
-23.50%
9.6M
-50.84%
19.5M
+25.56%
15.5M
+971.73%
Balance Sheet
Cash and Cash Equivalents
15.2M
-69.76%
50.2M
-26.25%
68.0M
-20.33%
85.4M
+3,778.14%
Short-Term Investments
366,316
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
15.5M
-69.03%
50.2M
-26.25%
68.0M
-20.33%
85.4M
+3,778.14%
Total Current Assets
22.4M
-55.64%
50.4M
-25.98%
68.1M
-20.29%
85.5M
+3,657.62%
Accumulated Depreciation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Property and Plant and Equipment and Net
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Assets
32.8M
+246.50%
9.5M
+84.51%
5.1M
0.00%
5.1M
+0.006%
Total Assets
55.2M
-7.91%
59.9M
-18.25%
73.3M
-19.14%
90.6M
+1,123.95%
Income Taxes Payable
335,846
+19.10%
281,976
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Current Liabilities
2.9M
-60.73%
7.4M
+1,165.17%
586,581
-16.72%
704,370
-2.82%
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
338,000
-97.39%
13.0M
N/A
N/A
N/A
N/A
N/A
Total Liabilities
3.3M
-83.93%
20.4M
+3,375.95%
586,581
-16.72%
704,370
-2.82%
Retained Earnings
-85.0M
-26.51%
-115.6M
-0.29%
-116.0M
+3.86%
-111.6M
+3.95%
Total Stockholders Equity
51.9M
+87.69%
27.6M
-61.97%
72.7M
-19.16%
89.9M
+1,246.21%
Total Shares Outstanding
6.8M
-15.45%
8.0M
-52.14%
16.8M
+956.17%
1.6M
0.00%
Cash Flow
Cash from Operating Activities
-3.0M
+38.43%
-2.2M
-43.29%
-3.8M
-7.86%
-4.1M
+23.61%
Capital Expenditures
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Investing Activities
-7.0M
+40.00%
-5.0M
N/A
0
N/A
0
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
-25.0M
+133.74%
-10.7M
-21.03%
-13.6M
-115.53%
87.3M
+1,783.00%
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return on Assets
40.60%
+8,001.40%
0.50%
+109.52%
-5.27%
-39.11%
-8.65%
-83.47%
Return on Equity
58.74%
+8,729.70%
0.67%
+112.53%
-5.31%
-39.52%
-8.78%
-85.46%
Revenue Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Ratio
7.68
+12.96%
6.80
-94.15%
116.18
-4.28%
121.38
+3,766.52%
Cash Ratio
5.21
-23.00%
6.76
-94.17%
115.99
-4.33%
121.24
+3,890.52%
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow